The $600m deal will create expanded pharma business for big bet on health care
Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Will an aging Japan be left with a hollow pharmaceutical industry?
US and Japanese M&A advisers poised for $180m payday
Weber foresees $1.4bn in annual cost savings
Japanese drugmaker plans to cut debt by half in 3-5 years to keep credit rating
Positive Wall Street cues also add to momentum